New Report Reveals Multiple Sclerosis Management And Treatment Options

BioTrends Research Group, Inc. recently announced the release of their latest annual report regarding the management and treatment of multiple sclerosis (MS) in the US, which is compiled using data obtained directly from MS patients who are currently receiving treatment in the form of disease modifying agents (DMAs).

The comprehensive report, titled ChartTrends: Multiple Sclerosis, includes information regarding MS patients receiving DMA treatments such as their demographic data, the prevalence of symptoms and symptomatic treatment, co-morbidities, concomitant medications, and also highlights factors that impact the decision making process of choosing between the various brands of DMA treatments available for first line patients, as well as switch patients.

There are several brands of DMA treatments available, including Avonex, Betaseron, Copaxone, Rebif and Tysabri, and MS patients being treated with these various brands differ from each other in terms of their MRI status, the likelihood of disease progression, and their clinical responses. This latest report has also taken into account several MS patient characteristics such as their disease classification and the current DMA treatment brand used, in order to identify the suitability of these patients for, and likelihood of, a potential switch to the newly approved drug Gilenya or late-stage DMAs in development such as Movectro, alemtuzumab, and daclizumab.